HTFL: Plaque Analysis growth and new trials drive expansion toward an $11B TAM by 2030
AI-driven coronary artery disease diagnostics are accelerating growth, with Plaque Analysis adoption and revenue surging, supported by robust clinical data and expanding payer coverage. Strategic RCTs target a $6B asymptomatic market, aiming for $11B TAM by 2030 and profitability by mid-2028.Based…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.